ArticleFrontiers in neurology2022
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial.Journal of Parkinson's disease · 2025Trial
- Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study.Brain sciences · 2026Article
- Opicapone in Parkinson's disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study.Clinical parkinsonism & related disorders · 2026Article
- Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson's Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study.Brain sciences · 2025Article
- Parkinson disease therapy: current strategies and future research priorities.Nature reviews. Neurology · 2024Review
- Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone in Parkinson's Disease.Drugs - real world outcomes · 2024Article
- Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone in Parkinson's Disease.Drugs - real world outcomes · 2024Article
- Real-world data of opicapone in patients with Parkinson's disease experiencing motor fluctuations: the OPTIMO study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Materials and methods: Data from matching treatment arms in BIPARK-I and II were combined for the placebo (PLC) and OPC 50 mg groups and exploratory Results: The Safety Set included 522 patients (PLC, Conclusion: OPC 50 mg was generally well-tolerated when used to treat patients with PD with end-of-dose fluctuations, with an even more favorable tolerability profile in patients who were earlier, as opposed to later, in their disease course and levodopa treatment pathway, further supporting its use as an early adjunct to levodopa in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.